ArticleThe American journal of pathology2014
Vascular endothelial growth factor acts primarily via platelet-derived growth factor receptor α to promote proliferative vitreoretinopathy.
Article in The American journal of pathology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04891991 (Treatment of Proliferative Vitreoretinopathy With Intravitreal Infliximab), which is not on this map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Treatment of Proliferative Vitreoretinopathy With Intravitreal Infliximab
Who cites it
36 citing papers in PubMed, 47 citations in OpenAlex.
- Bcl-2-Dependent Persistence of Mononuclear Phagocytes Promotes Ocular Fibrosis.International journal of molecular sciences · 2026Article
- Adjuvant mitomycin C during vitrectomy in young adults with primary nontraumatic rhegmatogenous retinal detachment and grade C proliferative vitreoretinopathy.BMC ophthalmology · 2026Article
- Aptamer-Based Delivery Systems for VEGF and NGF Modulation in Ocular Therapies.Advanced healthcare materials · 2026Review
- From fibrotic mechanisms to clinical translation: the drug therapy revolution and delivery system breakthrough in proliferative vitreoretinopathy.Frontiers in immunology · 2026Review
- Pathogenic mechanisms and treatment advances in proliferative vitreoretinopathy: A review.Medicine · 2025Review
- The efficacy of the three-port bimanual technique for direct perfluorocarbon liquid-silicone oil exchange in vitrectomy for the treatment of advanced proliferative vitreoretinopathy.BMC ophthalmology · 2025Article
- Development and validation of the Artificial Intelligence-Proliferative Vitreoretinopathy (AI-PVR) Insight system for deep learning-based diagnosis and postoperative risk prediction in proliferative vitreoretinopathy using multimodal fundus imaging.Quantitative imaging in medicine and surgery · 2025Article
- Management, risk factors and treatment outcomes of rhegmatogenous retinal detachment associated with giant retinal tears: scoping review.International journal of retina and vitreous · 2024Article
- Preoperative Intravitreal Conbercept Injection Reduced Both Angiogenic and Inflammatory Cytokines in Patients With Proliferative Diabetic Retinopathy.Journal of diabetes research · 2024Article
- Vitreous Levels of Vascular Endothelial Growth Factor and Platelet-Derived Growth Factor in Patients with Proliferative Diabetic Retinopathy: A Clinical Correlation.Biomolecules · 2023Article
- The Effect of Anti-Autotaxin Aptamers on the Development of Proliferative Vitreoretinopathy.International journal of molecular sciences · 2023Article
- Proliferative Vitreoretinopathy: A Reappraisal.Journal of clinical medicine · 2023Review
- Non-viral gene therapy using RNA interference with PDGFR-α mediated epithelial-mesenchymal transformation for proliferative vitreoretinopathy.Materials today. Bio · 2023Article
- Outcomes of chronic macula-off retinal detachment repair.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2023Article
- Vitreous humor proteome: unraveling the molecular mechanisms underlying proliferative and neovascular vitreoretinal diseases.Cellular and molecular life sciences : CMLS · 2022Review
- Mechanisms of Epithelial-Mesenchymal Transition and Prevention of Dispase-Induced PVR by Delivery of an Antioxidant αB Crystallin Peptide.Antioxidants (Basel, Switzerland) · 2022Article
- Large inferior retinectomies for proliferative vitreoretinopathy in silicone oil-filled eyes.International journal of retina and vitreous · 2022Article
- Proliferative diabetic retinopathy transcriptomes reveal angiogenesis, anti-angiogenic therapy escape mechanisms, fibrosis and lymphatic involvement.Scientific reports · 2021Article
- [Proliferative vitreoretinopathy prophylaxis : Mission (im)possible].Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft · 2021Review
- Managing PVR in the Era of Small Gauge Surgery.Journal of ophthalmology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Proliferative vitreoretinopathy (PVR) is a nonneovascular blinding disease and the leading cause for failure in surgical repair of rhegmatogenous retinal detachments. Once formed, PVR is difficult to treat. Hence, there is an acute interest in developing approaches to prevent PVR. Of the many growth factors and cytokines that accumulate in vitreous as PVR develops, neutralizing vascular endothelial growth factor (VEGF) A has recently been found to prevent PVR in at least one animal model. The goal of this study was to test if Food and Drug Administration-approved agents could protect the eye from PVR in multiple animal models and to further investigate the underlying mechanisms. Neutralizing VEGF with aflibercept (VEGF Trap-Eye) safely and effectively protected rabbits from PVR in multiple models of disease. Furthermore, aflibercept reduced the bioactivity of both experimental and clinical PVR vitreous. Finally, although VEGF could promote some PVR-associated cellular responses via VEGF receptors expressed on the retinal pigment epithelial cells that drive this disease, VEGF's major contribution to vitreal bioactivity occurred via platelet-derived growth factor receptor α. Thus, VEGF promotes PVR by a noncanonical ability to engage platelet-derived growth factor receptor α. These findings indicate that VEGF contributes to nonangiogenic diseases and that anti-VEGF-based therapies may be effective on a wider spectrum of diseases than previously appreciated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.